Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download The Influence Of The Pharmaceutical Industry PDF full book. Access full book title The Influence Of The Pharmaceutical Industry.
| Author | : Great Britain: Parliament: House of Commons: Health Committee |
| Publisher | : The Stationery Office |
| Total Pages | : 556 |
| Release | : 2005-04-26 |
| Genre | : Political Science |
| ISBN | : 9780215024572 |
Incorporating HC 1030-i to iii.
| Author | : Katherine Fierlbeck |
| Publisher | : University of Toronto Press |
| Total Pages | : 303 |
| Release | : 2021 |
| Genre | : Pharmaceutical policy |
| ISBN | : 148752904X |
Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry to account through greater transparency.
| Author | : Jerome P. Kassirer M.D. |
| Publisher | : Oxford University Press |
| Total Pages | : 272 |
| Release | : 2004-10-18 |
| Genre | : Medical |
| ISBN | : 9780198039297 |
We all know that doctors accept gifts from drug companies, ranging from pens and coffee mugs to free vacations at luxurious resorts. But as the former Editor-in-Chief of The New England Journal of Medicine reveals in this shocking expose, these innocuous-seeming gifts are just the tip of an iceberg that is distorting the practice of medicine and jeopardizing the health of millions of Americans today. In On the Take, Dr. Jerome Kassirer offers an unsettling look at the pervasive payoffs that physicians take from big drug companies and other medical suppliers, arguing that the billion-dollar onslaught of industry money has deflected many physicians' moral compasses and directly impacted the everyday care we receive from the doctors and institutions we trust most. Underscored by countless chilling untold stories, the book illuminates the financial connections between the wealthy companies that make drugs and the doctors who prescribe them. Kassirer details the shocking extent of these financial enticements and explains how they encourage bias, promote dangerously misleading medical information, raise the cost of medical care, and breed distrust. Among the questionable practices he describes are: the disturbing number of senior academic physicians who have financial arrangements with drug companies; the unregulated "front" organizations that advocate certain drugs; the creation of biased medical education materials by the drug companies themselves; and the use of financially conflicted physicians to write clinical practice guidelines or to testify before the FDA in support of a particular drug. A brilliant diagnosis of an epidemic of greed, On the Take offers insight into how we can cure the medical profession and restore our trust in doctors and hospitals.
| Author | : Ben Goldacre |
| Publisher | : Macmillan |
| Total Pages | : 479 |
| Release | : 2014-04 |
| Genre | : Business & Economics |
| ISBN | : 0865478066 |
Argues that doctors are deliberately misinformed by profit-seeking pharmaceutical companies that casually withhold information about drug efficacy and side effects, explaining the process of pharmaceutical data manipulation and its global consequences. By the best-selling author of Bad Science.
| Author | : Anna Laskai |
| Publisher | : Springer Nature |
| Total Pages | : 298 |
| Release | : 2020-05-06 |
| Genre | : Social Science |
| ISBN | : 3030447901 |
This book discusses the influence of the pharmaceutical industry on the practice of medicine, and the observed and potential pitfalls of such partnerships. It argues that the pharmaceutical industry has become indispensable to many of the activities of the medical profession across the pharmaceutical product lifecycle, and examines the regulatory, ethical, professional and institutional difficulties that arise from these interactions. With data drawn from over 80 qualitative accounts from medical, pharmaceutical, regulatory and healthcare professionals, this book uses both Hungary and the Netherlands as case studies to demonstrate the potential problem of undue pharmaceutical industry influence within the relationships fostered with the profession of medicine. Chapters systematically describe the lifecycle of a pharmaceutical product from research to distribution, demonstrating the interdependency of industry and medicine. Arguing that the medical profession should be a buffer between the pharmaceutical industry interests and patient interests, the book explores how undue industry influence weakens the ability of the medical profession to do so. Using the theory of institutional corruption, the book aims to analyze how conflict of interest and the weakening of institutional imperatives is a result of institutional interactions rather than individual actions. Appropriate for students and researchers of the pharmaceutical industry, corporate corruption, and those working in NGOs and policy making, this unique volume is an comprehensive look at the complex relationship between medicine and pharmacy.
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 235 |
| Release | : 2018-03-01 |
| Genre | : Medical |
| ISBN | : 0309468086 |
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
| Author | : |
| Publisher | : |
| Total Pages | : |
| Release | : |
| Genre | : |
| ISBN | : |
| Author | : Marcia Angell |
| Publisher | : Random House Trade Paperbacks |
| Total Pages | : 354 |
| Release | : 2005-08-09 |
| Genre | : Business & Economics |
| ISBN | : 0375760946 |
During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become–and argues for essential, long-overdue change. Currently Americans spend a staggering $200 billion each year on prescription drugs. As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and development are unfounded: The truth is that drug companies funnel the bulk of their resources into the marketing of products of dubious benefit. Meanwhile, as profits soar, the companies brazenly use their wealth and power to push their agenda through Congress, the FDA, and academic medical centers. Zeroing in on hugely successful drugs like AZT (the first drug to treat HIV/AIDS), Taxol (the best-selling cancer drug in history), and the blockbuster allergy drug Claritin, Dr. Angell demonstrates exactly how new products are brought to market. Drug companies, she shows, routinely rely on publicly funded institutions for their basic research; they rig clinical trials to make their products look better than they are; and they use their legions of lawyers to stretch out government-granted exclusive marketing rights for years. They also flood the market with copycat drugs that cost a lot more than the drugs they mimic but are no more effective. The American pharmaceutical industry needs to be saved, mainly from itself, and Dr. Angell proposes a program of vital reforms, which includes restoring impartiality to clinical research and severing the ties between drug companies and medical education. Written with fierce passion and substantiated with in-depth research, The Truth About the Drug Companies is a searing indictment of an industry that has spun out of control.
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 225 |
| Release | : 1991-02-01 |
| Genre | : Medical |
| ISBN | : 030904491X |
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
| Author | : Helge L. Waldum |
| Publisher | : |
| Total Pages | : 0 |
| Release | : 2023-04-24 |
| Genre | : |
| ISBN | : 9781527599895 |
This book is based upon 45 years of clinical and scientific experience with gastroenterology, especially the stomach. In clinical medicine, Marshall and Warren's assertion that Helicobacter pylori is the main cause of gastritis, peptic ulcer disease, and gastric cancer made an immense impact. However, although peptic ulcers now can be treated with antibiotics, drugs that inhibit gastric acid secretion, including proton pump inhibitors (PPIs), are used in up to 10% of the adult population in Western countries in the treatment of gastro-oesophageal reflux disease and dyspepsia. For a long time, PPIs were the most frequently sold drugs, which made their economic impact huge. The reduction of gastric acidity induces the release of the gastric hormone gastrin, which stimulates its target, the ECL cell, to release histamine; this subsequently augments the acid secretion from the parietal cell. Gastrin also stimulates ECL cell proliferation, and long-term hyperstimulation leads to the development of tumors. The author of this book began his studies into the role of the ECL cell in human gastric carcinomas by demonstrating ECL cell markers in gastric cancer cells. This incriminated the ECL and its main regulator, gastrin, in gastric carcinogenesis. Every condition with reduced gastric acidity including treatment with drugs inhibiting acid secretion, leads to increased gastrin and thus to a predisposition to gastric cancer. This short book provides ample evidence of the pharmaceutical industry's influence on medical science. It also highlights the lack of respect and attention that the medical world gives to a biological function like gastric acidity, which prevents microbes, including viruses and prions, from entering the body through the gut.
